Document is current
Any future updates will be listed below
-
Authors
Jukema, Ruurt A.
Ahmed, Tarek A. N.
Tardif, Jean-Claude
- License Information
-
More Information
Article History
Received: 4 July 2019
Accepted: 26 September 2019
First Online: 1 November 2019
Ethics approval and consent to participate
: Not available.
: RAJ and TANA declare that they have no competing interest to report. J-CT reports the following potential competing interests: has received grant support from Amarin, AstraZeneca, Esperion, and Ionis; has received grant support and consulting fees from DalCor and Servier; has received grant support and fees for serving as co-chairman of an executive committee from Pfizer; has received grant support and fees for serving on an executive committee from Sanofi; holds a minor equity interest in DalCor; and has received a patent (U.S. 9,909,178 B2) for dalcetrapib for therapeutic use.
